Related Experiment Video
Updated: Jun 28, 2025

Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
Efficacy of Rivastigmine Augmentation on Positive and Negative Symptoms, General Psychopathology, and Quality of Life
Sepideh Herizchi1, Ali Reza Shafiee-Kandjani2, Mostafa Farahbakhsh3
1Herizchi, Associate Professor of Psychiatry, Research Center of Psychiatry and Behavioral Sciences, Tabriz University of Medical Science, Tabriz, Iran, ORCID: 0000-0002-0299-1122.
Abstract:
The study aimed to assess Rivastigmine augmentation on positive and negative symptoms (PNSs), general psychopathology, and quality of life in patients with chronic Schizophrenia. A double-blind, parallel-design, randomized, placebo-controlled trial of 60 schizophrenia patients was conducted. Intervention group received rivastigmine 3 mg/day + Treatment as Usual (TAU) and the control group: TAU + placebo. Negative and positive symptoms, general psychopathology; and quality of life were measured using Positive and Negative Symptom Scale (PANSS) and Manchester Short Assessment of Quality of Life (MANSA). T-test, ANOVA, and the general univariate linear model tests were used for the analyses. Out of 60 participants, 52 (86.6%) were male. At baseline, no significant relationship was found for demographic and clinical characteristics between intervention and control groups. Between-group analysis indicated that all outcome measures PNSs, general psychopathology symptoms, and QoL score in rivastigmine group was significantly improved (p = 0.001). According to within-group analysis, a significant association was found between Rivastigmine and placebo groups in PNSs (p < 0.05). Rivastigmine augmentation improved PNSs and psychopathology in schizophrenia patients. However, no significant association found for improving the life quality after 8 weeks treatment.
More Related Videos
08:54Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
Published on: June 6, 2025
10:15Utilizing Repetitive Transcranial Magnetic Stimulation to Improve Language Function in Stroke Patients with Chronic Non-fluent Aphasia
Published on: July 2, 2013
Related Concept Videos
Alzheimer's Disease: Treatment
Psychosis: Goals of Pharmacotherapy
Drug Therapy
Antianxiety Medications
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Psychosis and Antipsychotic Drugs: Overview
Antidepressant Drugs: MAOIs and Other Agents